(2)
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2021(NYSE: PKI), today announced that its T-SPOT
Discovery SARS-CoV-2 kit will be used for T cell testing in the DIRECT study. Oxford Immunotec is collaborating with researchers at the University of Leicester on DIRECT (Determining the Immune Response in Ethnic minority healthcare workers to COVID-19 infection). The study, funded through the National Core Studies group, is actively recruiting healthcare workers in Leicester for detailed analysis of their immune response to infection and / or vaccination (including T cells). This analysis, together with information collected through online questionnaires, will enable researchers to understand whether there are differences in the immune response in different ethnic minority groups, including whether there are differences in the magnitude and duration of this response.
Oxford Immunotec Global Limite
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2021 (GLOBE NEWSWIRE) Oxford Immunotec a global, high-growth diagnostics company part of PerkinElmer (NYSE: PKI), today announced that its T-SPOT
®
Discovery SARS-CoV-2 kit will be used for T cell testing in the DIRECT study. Oxford Immunotec is collaborating with researchers at the University of Leicester on DIRECT (Determining the Immune Response in Ethnic minority healthcare workers to COVID-19 infection). The study, funded through the National Core Studies group, is actively recruiting healthcare workers in Leicester for detailed analysis of their immune response to infect
Oxford Immunotec’s COVID-19 test to be used in ‘mix and match’ UK vaccine trial
28th April 2021
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 test kit is set to be used for T cell testing in the UK Com-Cov trial, which is evaluating different combinations of approved COVID-19 vaccines.
The Com-Cov study will be the first in the world to evaluate the effects of using different vaccines for the first and second dose within a two-dose vaccination regimen.
It will be run by the National Immunisation Schedule Evaluation Consortium (NISEC) across eight National Institute for Health Research (NIHR) supported sites.
The first stage of the programme has recruited 830 participants already and has recently expanded to include a second stage recruiting an additional 1,050 participants aged over 50 years old.
Oxford Immunotec s T-SPOT Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Search jobs 09-Mar-2021 Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE marks T-SPOT
®.
COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 8
th, 2021 – Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.
COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test.